CAH Cardinal Health, Inc. Common Stock
NYSE · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 11, 2026CAH 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
CAH 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2001年4月23日 | 3-for-2 | 正向 |
| 1998年11月2日 | 3-for-2 | 正向 |
| 1996年12月17日 | 3-for-2 | 正向 |
| 1994年7月1日 | 5-for-4 | 正向 |
| 1991年10月1日 | 5-for-4 | 正向 |
| 1990年10月1日 | 5-for-4 | 正向 |
| 1989年10月2日 | 5-for-4 | 正向 |
| 1988年9月9日 | 11-for-10 | 正向 |
| 1987年9月9日 | 11-for-10 | 正向 |
关于 Cardinal Health, Inc. Common Stock 公司概况（来自维基百科）
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | CAH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | 32.95年均值 ≈29.4 | ≈29.4 | 22.9 | 估值过高 | |
| PEG Ratio (市盈率增长比) | ≈1.2 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | CAH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 毛利率 (TTM) | 3.8%5年均值 ≈3.5% | ≈3.5% | 4.3% | 弱 | |
| 营业利润率 (TTM) | 1.0%5年均值 ≈0.52% | ≈0.52% | 1.1% | 持平 | |
| 息税折旧摊销前利润率 (TTM) | 1.4%5年均值 ≈0.88% | ≈0.88% | 1.3% | 持平 | |
| 税前利润率 (TTM) | 0.86%5年均值 ≈0.44% | ≈0.44% | 1.0% | 低于平均水平 | |
| 净利润率 (TTM) | 0.67%5年均值 ≈0.27% | ≈0.27% | 0.63% | 持平 | |
| ROA | 3.1%5年均值 ≈1.3% | ≈1.3% | 3.1% | 持平 | |
| ROE | -60.5%5年均值 ≈-65.5% | ≈-65.5% | -4.6% | 弱 | |
| ROIC | -71.1%5年均值 ≈-13.6% | ≈-13.6% | 12.2% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | CAH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 0.95年均值 ≈1.0 | ≈1.0 | 0.9 | 低流动性 | |
| Quick Ratio (速动比率) | 0.45年均值 ≈0.5 | ≈0.5 | 0.5 | 低流动性 | |
| Interest Coverage (利息保障倍数) | 7.55年均值 ≈9.3 | ≈9.3 | 5.9 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | CAH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 14.2%5年均值 ≈9.5% | ≈9.5% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 7.4%5年均值 ≈9.1% | ≈9.1% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 9.4% | · | · | · | |
| EPS YoY | 12.1%5年均值 ≈91.0% | ≈91.0% | · | · | |
| Net Income YoY (净利润同比增长) | 9.8%5年均值 ≈83.7% | ≈83.7% | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | 79.0% | · | · | · | |
| EPS CAGR 5Y (每股收益年复合增长率（5年）) | 28.3% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 73.2% | · | · | · | |
| Net Income CAGR 5Y (净利润年复合增长率（5年）) | 22.9% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | CAH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 4.65年均值 ≈4.6 | ≈4.6 | 4.5 | 顶尖 | |
| Inventory Turnover (库存周转率) | 14.35年均值 ≈13.2 | ≈13.2 | 15.7 | 弱 | |
| Receivables Turnover (应收账款周转率) | 18.85年均值 ≈18.6 | ≈18.6 | 13.1 | 顶尖 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$4.3M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 | 货币 | 收益率 |
|---|---|---|---|
| 十月 1, 2026 | $0.52 | USD | ≈0.89% |
| 七月 1, 2026 | $0.52 | USD | ≈0.86% |
| 四月 1, 2026 | $0.51 | USD | ≈0.96% |
| 一月 2, 2026 | $0.51 | USD | ≈0.99% |
| 十月 1, 2025 | $0.51 | USD | ≈1.3% |
| 七月 1, 2025 | $0.51 | USD | ≈1.2% |
| 四月 1, 2025 | $0.51 | USD | ≈1.5% |
| 一月 2, 2025 | $0.51 | USD | ≈1.7% |
| 十月 1, 2024 | $0.51 | USD | ≈1.8% |
| 七月 1, 2024 | $0.51 | USD | ≈2.1% |
| 三月 28, 2024 | $0.50 | USD | ≈1.8% |
| 十二月 29, 2023 | $0.50 | USD | ≈2.0% |
| 十月 2, 2023 | $0.50 | USD | ≈2.3% |
| 六月 30, 2023 | $0.50 | USD | ≈2.1% |
| 三月 31, 2023 | $0.50 | USD | ≈2.6% |
| 十二月 30, 2022 | $0.50 | USD | ≈2.6% |
| 九月 30, 2022 | $0.50 | USD | ≈3.0% |
| 六月 30, 2022 | $0.50 | USD | ≈3.8% |
| 三月 31, 2022 | $0.49 | USD | ≈3.5% |
| 十二月 31, 2021 | $0.49 | USD | ≈3.8% |
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年12月31日 | 八月 11, 2026 | $2.91 | $2.44 | 19.1% |
| 2026年6月30日 | $2.60 | $2.44 | 6.4% | |
| 2026年3月31日 | $3.17 | $2.82 | 12.6% | |
| 2025年12月31日 | $2.63 | $2.40 | 9.4% | |
| 2025年9月30日 | $2.55 | $2.20 | 15.9% | |
| 2025年6月30日 | $2.08 | $2.06 | 1.1% | |
| 2025年3月31日 | $2.35 | $2.19 | 7.4% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
资产负债表
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
现金流
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
盈利能力
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
流动性与偿付能力
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
效率
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
每股
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $1072.78 | $919.74 | $918.33 | $782.49 | $650.05 | $552.61 | $521.92 | $483.50 | $434.31 | $406.18 | $368.32 | $306.06 | |
| Cash Flow / Share | $21.83 | $9.90 | $15.23 | $10.84 | $11.19 | $8.26 | $6.69 | $9.04 | $8.79 | $3.70 | $9.00 | $7.58 | |
| Dividend Paid / Share | $2.04 | $2.02 | $2.00 | $1.98 | $1.96 | $1.94 | $1.92 | $1.91 | $1.85 | $1.80 | $1.55 | $1.37 | |
| EPS (TTM) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 |
增长率
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
损益表
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | · | 235,000,000 | 236,000,000 | 238,000,000 | · | 240,000,000 | 242,000,000 | 243,000,000 | · | 243,000,000 | 245,000,000 | 249,000,000 | · | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | · | 236,000,000 | 237,000,000 | 239,000,000 | · | 241,000,000 | 243,000,000 | 245,000,000 | · | 245,000,000 | 246,000,000 | 249,000,000 | · | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
资产负债表
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
现金流
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
盈利能力
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
流动性与偿付能力
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
效率
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
每股
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $258.22 | $276.91 | $267.82 | · | $227.71 | $227.42 | $213.38 | · | $224.13 | $233.52 | $219.05 | · | $195.69 | $197.20 | $181.70 | |
| Cash Flow / Share | · | · | · | $4.07 | · | · | · | $-6.72 | · | · | · | $2.18 | · | · | · | $0.08 | |
| Dividend / Share | · | $0.51 | $0.51 | $0.51 | · | $0.51 | $0.51 | $0.51 | · | $0.50 | $0.50 | $0.50 | · | $0.50 | $0.50 | $0.50 |
估值 (TTM)
| 指标 | 趋势 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $250.74B | $244.67B | $234.31B | · | $222.29B | $222.28B | $224.45B | · | $220.38B | $216.01B | $210.04B | · | $198.62B | $192.96B | $186.95B | |
| Net Income TTM | · | $1.55B | $1.66B | $1.59B | · | $1.56B | $1.31B | $1.28B | · | $622M | $726M | $281M | · | $519M | $-1.24B | $-1.11B | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% | |
| Annual Payout | · | $491M | $495M | $495M | · | $496M | $494M | $496M | · | $503M | $509M | $514M | · | $533M | $541M | $552M |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| 收入 | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| 毛利率 % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| 营业利润率 % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| 净收入 | $1.71B | $1.56B | $852M | $330M | $-938M |
| 稀释后每股收益 (EPS) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
| 指标 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| 流动比率 | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| 速动比率 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
| 指标 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| 自由现金流 | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
机构持有人 (13F) 1605 家申报者 · $54.4B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 156 (-26 与上一季度对比) | 81 (-19 与上一季度对比) | 530 (-24 与上一季度对比) | 574 (+58 与上一季度对比) | +7.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6461178523 | 31441258 | 11.88% | 股份 |
| BlackRock, Inc. | $6293114912 | 26490633 | 11.57% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3632811706 | 15292186 | 6.68% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $3530205977 | 14860271 | 6.49% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3258822899 | 13717894 | 5.99% | 股份 |
| STATE STREET CORP | $2842909265 | 11967121 | 5.23% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $1531751894 | 6472810 | 2.82% | 股份 |
| Invesco Ltd. | $1126646236 | 4742576 | 2.07% | 股份 |
| MORGAN STANLEY | $1098793649 | 4625329 | 2.02% | 股份 |
| WCM INVESTMENT MANAGEMENT, LLC | $971445537 | 4112461 | 1.79% | 股份 |
| NORGES BANK | $885248810 | 3726422 | 1.63% | 股份 |
| BANK OF AMERICA CORP /DE/ | $689065528 | 2900596 | 1.27% | 股份 |
| NORTHERN TRUST CORP | $681536598 | 2868903 | 1.25% | 股份 |
| JPMORGAN CHASE & CO | $630412357 | 2668749 | 1.16% | 股份 |
| GOLDMAN SACHS GROUP INC | $566588458 | 2385033 | 1.04% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $499624076 | 2103149 | 0.92% | 股份 |
| FMR LLC | $490857853 | 2066248 | 0.90% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $490754373 | 2322438 | 0.90% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $469793667 | 1977579 | 0.86% | 股份 |
| Legal & General Group Plc | $438869762 | 1847406 | 0.81% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $411645774 | 1732808 | 0.76% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $369172278 | 1554017 | 0.68% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $315702986 | 1328940 | 0.58% | 股份 |
| AMERIPRISE FINANCIAL INC | $311391613 | 1310794 | 0.57% | 股份 |
| NORDEA INVESTMENT MANAGEMENT AB | $308748216 | 1297534 | 0.57% | 股份 |
| Bank of New York Mellon Corp | $308639982 | 1299209 | 0.57% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $281612012 | 1185468 | 0.52% | 股份 |
| Robeco Institutional Asset Management B.V. | $258918781 | 1089909 | 0.48% | 股份 |
| DEUTSCHE BANK AG\ | $238933097 | 1005780 | 0.44% | 股份 |
| ENVESTNET ASSET MANAGEMENT INC | $230523823 | 970390 | 0.42% | 股份 |
| JANE STREET GROUP, LLC | $225610732 | 949700 | 0.41% | 卖出期权 |
| Man Group plc | $222013123 | 934556 | 0.41% | 股份 |
| WELLS FARGO & COMPANY/MN | $219711690 | 924868 | 0.40% | 股份 |
| UBS Group AG | $218780954 | 920950 | 0.40% | 股份 |
| Amundi | $211809683 | 891605 | 0.39% | 股份 |
| Nuveen, LLC | $211731009 | 891274 | 0.39% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $203800043 | 857888 | 0.37% | 股份 |
| ProShare Advisors LLC | $197187154 | 830052 | 0.36% | 股份 |
| ROYAL BANK OF CANADA | $185518000 | 780931 | 0.34% | 股份 |
| BARCLAYS PLC | $177344480 | 746525 | 0.33% | 股份 |
| FEDERATED HERMES, INC. | $176399992 | 742549 | 0.32% | 股份 |
| SEI INVESTMENTS CO | $173413944 | 729965 | 0.32% | 股份 |
| JANE STREET GROUP, LLC | $169712864 | 714400 | 0.31% | 买入期权 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $163869121 | 693714 | 0.30% | 股份 |
| Allianz Asset Management GmbH | $163833492 | 689651 | 0.30% | 股份 |
| Swedbank AB | $159718953 | 672331 | 0.29% | 股份 |
| Swiss National Bank | $157644816 | 663600 | 0.29% | 股份 |
| JANUS HENDERSON GROUP PLC | $155390858 | 735467 | 0.29% | 股份 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141722832 | 596577 | 0.26% | 股份 |
| 1832 Asset Management L.P. | $139039117 | 585280 | 0.26% | 股份 |
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 申报 | 2014年6月5日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2004年7月2日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2004年5月28日 | · | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 84 位内幕人士 · 45 位高管 · 37 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jason M. Hollar | Chief Executive Officer | 2026年8月19日 S | 190603 | 0 | 10 | $-29375516 |
| Deborah Weitzman | CEO, PSS Segment | 2026年8月18日 S | 77901 | 0 | 3 | $-1731524 |
| Stephen M Mason | CEO, GMPD Segment | 2026年8月18日 S | 18061 | 0 | 4 | $-8274118 |
| Michael C Kaufmann | CEO | 2022年8月15日 M | 601065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | 2022年8月15日 F | 105699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | 2019年8月15日 F | 61387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | 2017年9月15日 F | 146503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | 2012年2月27日 M | 89204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | 2009年9月1日 A | 238635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | 2007年9月2日 F | 68041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | 2006年5月16日 M | 36082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | 2004年12月13日 A | 14400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | 2026年8月18日 S | 20495 | 0 | 5 | $-10451104 |
| Jorge M Gomez | Chief Financial Officer | 2018年11月8日 F | 39582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | 2014年8月27日 M | 67190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | 2003年11月17日 A | · | 0 | 0 | $0 |
| George L Fotiades | President & COO | 2003年1月15日 P | 80278 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | 2026年8月19日 S | 2811 | 0 | 2 | $-546473 |
| Michelle D. Greene | Chief Information Officer | 2026年8月18日 S | 10330 | 0 | 6 | $-3373574 |
| Jessica L Mayer | Chief Legal/Compliance Officer | 2026年8月18日 S | 33076 | 0 | 4 | $-6952485 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 2026年8月15日 F | 11757 | 0 | 0 | $0 |
| Ola M Snow | Chief Human Resources Officer | 2025年12月1日 F | 15111 | 0 | 0 | $0 |
| Patricia M English | Chief Accounting Officer | 2022年8月15日 F | 9000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | 2022年8月15日 F | 37850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | 2022年8月15日 F | 44491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | 2020年8月15日 F | 12289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | 2018年12月3日 F | 126301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | 2018年8月31日 F | 30725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | 2018年8月15日 F | 22612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | 2018年8月15日 F | 502630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | 2016年5月20日 M | 31585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | 2015年11月30日 G | 32455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | 2015年11月17日 F | 16760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | 2014年11月7日 M | 20409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | 2008年11月1日 F | 50886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | 2008年9月26日 A | 39594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | 2007年11月26日 I | 1740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | 2007年6月4日 M | 8573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | 2006年9月2日 F | 85978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | 2005年9月6日 G | 55382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | 2005年9月2日 A | 6137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | 2005年9月2日 A | 4607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | 2005年2月17日 G | 7000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | 2004年8月23日 A | 2462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | 2004年2月24日 M | 31039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | 董事 | 2026年4月15日 A | 28645 | 0 | 1 | $-918880 |
| Michelle Brennan | 董事 | 2025年11月5日 A | 8086 | 0 | 0 | $0 |
| Robert Azelby | 董事 | 2025年11月5日 A | 4085 | 0 | 0 | $0 |
| Nancy Killefer | 董事 | 2025年11月5日 A | 27624 | 0 | 0 | $0 |
| Akhil Johri | 董事 | 2025年11月5日 A | 22868 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | 董事 | 2025年11月5日 A | 2116 | 0 | 0 | $0 |
| Sheri H. Edison | 董事 | 2025年11月5日 A | 14848 | 0 | 0 | $0 |
| Christine Mundkur | 董事 | 2025年11月5日 A | 7536 | 0 | 0 | $0 |
| Gregory B Kenny | 董事 | 2025年11月5日 A | 64194 | 0 | 0 | $0 |
| Steven Barg | 董事 | 2023年11月15日 A | 4739 | 0 | 0 | $0 |
| Sujatha Chandrasekaran | 董事 | 2023年11月15日 A | 4739 | 0 | 0 | $0 |
| Bruce Downey | 董事 | 2022年11月9日 A | 53929 | 0 | 0 | $0 |
| COX CARRIE SMITH | 董事 | 2022年11月9日 A | 41631 | 0 | 0 | $0 |
| Dean A Scarborough | 董事 | 2022年10月18日 A | 11138 | 0 | 0 | $0 |
| John H Weiland | 董事 | 2021年11月11日 A | 11138 | 0 | 0 | $0 |
| Michael J Losh | 董事 | 2021年10月15日 A | 9988 | 0 | 0 | $0 |
| Calvin Darden | 董事 | 2020年11月9日 A | 39616 | 0 | 0 | $0 |
| Colleen F. Arnold | 董事 | 2019年11月12日 A | 35103 | 0 | 0 | $0 |
| David J Anderson | 董事 | 2018年1月16日 A | 9946 | 0 | 0 | $0 |
| David P King | 董事 | 2017年11月8日 A | 21044 | 0 | 0 | $0 |
| Clayton M Jones | 董事 | 2017年5月8日 S | 0 | 0 | 0 | $0 |
| NOTEBAERT RICHARD C | 董事 | 2015年3月3日 M | 35778 | 0 | 0 | $0 |
| John F Finn | 董事 | 2014年11月5日 A | 21074 | 0 | 0 | $0 |
| Glenn Britt | 董事 | 2014年5月7日 A | 18314 | 0 | 0 | $0 |
| Jean G Spaulding | 董事 | 2013年11月6日 A | 17182 | 0 | 0 | $0 |
| David W Raisbeck | 董事 | 2011年11月2日 A | 17075 | 0 | 0 | $0 |
| James J Mongan MD | 董事 | 2010年11月3日 A | 7150 | 0 | 0 | $0 |
| Philip L Francis | 董事 | 2009年9月1日 D | 1021 | 0 | 0 | $0 |
| John B Mccoy | 董事 | 2008年11月5日 A | 2721 | 0 | 0 | $0 |
| Robert D Walter | 董事 | 2008年10月6日 M | 1531235 | 0 | 0 | $0 |
| Matthew D Walter | 董事 | 2008年1月7日 G | 2232 | 0 | 0 | $0 |
| Robert L Gerbig | 董事 | 2007年2月12日 M | 66218 | 0 | 0 | $0 |
| John F Havens | 董事 | 2006年11月8日 A | 30973 | 0 | 0 | $0 |
| David Bing | 董事 | 2005年8月3日 A | 3669 | 0 | 0 | $0 |
| Robert W Musslewhite | · | 2025年11月5日 A | 2116 | 0 | 0 | $0 |
| David C Evans | · | 2025年11月5日 A | 15373 | 0 | 0 | $0 |
| David L Schlotterbeck | · | 2009年9月1日 D | 61523 | 0 | 0 | $0 |
| Michael D Ohalleran | · | 2009年9月1日 D | 8458 | 0 | 0 | $0 |
| George N Conrades | · | 2008年11月5日 A | 2653 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 148 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| PEZ · Invesco Exchange-Traded Fund Trust | 5.29% | 4961 SH | 2026年10月2日 | 每日 |
| FXG · First Trust Exchange-Traded Alpha... | 3.15% | 31414 NS | 2026年7月31日 | N-PORT |
| STNC · Hennessy Funds Trust | 2.97% | 12009 NS | 2026年7月31日 | N-PORT |
| IYK · iShares Trust | 2.56% | 150019 SH | 2026年9月11日 | 每日 |
| NUMV · Nushares ETF Trust | 2.30% | 44435 NS | 2026年7月31日 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Inde... | 2.09% | 14948 SH | 2026年10月2日 | 每日 |
| SMRI · EA Series Trust | 1.84% | 51638 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.59% | 59923 SH | 2026年10月2日 | 每日 |
| NULV · Nushares ETF Trust | 1.53% | 145860 NS | 2026年7月31日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 1.51% | 597 NS | 2026年7月31日 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.49% | 228600 NS | 2026年7月31日 | N-PORT |
| COWZ · Pacer Funds Trust | 1.47% | 1193309 NS | 2026年7月31日 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 1.34% | 23570 SH | 2026年8月19日 | 每日 |
| UPSD · ETF Series Solutions | 1.31% | 6646 NS | 2026年7月31日 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trus... | 1.25% | 527725 SH | 2026年10月2日 | 每日 |
| SRHQ · Elevation Series Trust | 1.20% | 11056 NS | 2026年7月31日 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 1.11% | 6347 SH | 2026年10月2日 | 每日 |
| RPV · Invesco Exchange-Traded Fund Trust | 1.10% | 79806 SH | 2026年10月2日 | 每日 |
| ESMV · iShares Trust | 1.06% | 350 SH | 2026年9月11日 | 每日 |
| PDP · Invesco Exchange-Traded Fund Trust | 1.06% | 67986 SH | 2026年10月2日 | 每日 |
| VOE · VANGUARD INDEX FUNDS | 0.96% | 1504470 SH | 2026年8月19日 | 每日 |
| ABFL · Abacus FCF ETF Trust | 0.92% | 21099 NS | 2026年7月31日 | N-PORT |
| VAMO · Cambria ETF Trust | 0.87% | 4124 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.82% | 707389 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.78% | 111939 NS | 2026年7月31日 | N-PORT |
| IWP · iShares Trust | 0.74% | 604324 SH | 2026年9月11日 | 每日 |
| LSEQ · Harbor ETF Trust | 0.70% | 468 NS | 2026年7月31日 | N-PORT |
| IXJ · iShares Trust | 0.70% | 123272 SH | 2026年9月11日 | 每日 |
| CURE · Direxion Shares ETF Trust | 0.62% | 4609 NS | 2026年7月31日 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.59% | 4662 NS | 2026年7月31日 | N-PORT |
| FTC · First Trust Exchange-Traded Alpha... | 0.55% | 31604 NS | 2026年7月31日 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.54% | 5075476 SH | 2026年8月19日 | 每日 |
| FTLS · First Trust Exchange-Traded Fund III | 0.51% | 54815 NS | 2026年7月31日 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Inde... | 0.47% | 19654 SH | 2026年10月2日 | 每日 |
| LGDX · Tidal Trust III | 0.44% | 2735 NS | 2026年7月31日 | N-PORT |
| EVUS · iShares Trust | 0.43% | 6970 SH | 2026年9月11日 | 每日 |
| RECS · Columbia ETF Trust I | 0.43% | 108869 NS | 2026年7月31日 | N-PORT |
| IMCG · iShares Trust | 0.42% | 71722 SH | 2026年9月11日 | 每日 |
| QLC · FlexShares Trust | 0.42% | 18368 NS | 2026年7月31日 | N-PORT |
| IWR · iShares Trust | 0.41% | 959539 SH | 2026年9月11日 | 每日 |
| LCOW · Pacer Funds Trust | 0.40% | 454 NS | 2026年7月31日 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.39% | 11919 NS | 2026年7月31日 | N-PORT |
| IMCB · iShares Trust | 0.39% | 27470 SH | 2026年9月11日 | 每日 |
| JPME · J.P. Morgan Exchange-Traded Fund ... | 0.36% | 7324 NS | 2026年7月31日 | N-PORT |
| REVS · Columbia ETF Trust I | 0.36% | 5200 NS | 2026年7月31日 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund ... | 0.36% | 7082 NS | 2026年7月31日 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trus... | 0.35% | 445000 | 2026年10月2日 | 每日 |
| IMCV · iShares Trust | 0.35% | 16989 SH | 2026年9月11日 | 每日 |
| ACWV · iShares, Inc. | 0.33% | 46363 SH | 2026年9月11日 | 每日 |
| BSCT · Invesco Exchange-Traded Self-Inde... | 0.32% | 9479000 | 2026年10月2日 | 每日 |
| XOEF · iShares Trust | 0.31% | 293 SH | 2026年9月11日 | 每日 |
| IWS · iShares Trust | 0.29% | 189265 SH | 2026年9月11日 | 每日 |
| JMOM · J.P. Morgan Exchange-Traded Fund ... | 0.28% | 30714 NS | 2026年7月31日 | N-PORT |
| GLOF · iShares Trust | 0.28% | 2389 SH | 2026年9月11日 | 每日 |
| BSCR · Invesco Exchange-Traded Self-Inde... | 0.28% | 12847000 | 2026年10月2日 | 每日 |
| FAD · First Trust Exchange-Traded Alpha... | 0.27% | 6869 NS | 2026年7月31日 | N-PORT |
| ESGU · iShares Trust | 0.26% | 200383 SH | 2026年9月11日 | 每日 |
| FEX · First Trust Exchange-Traded Alpha... | 0.26% | 17795 NS | 2026年7月31日 | N-PORT |
| NULC · Nushares ETF Trust | 0.26% | 796 NS | 2026年7月31日 | N-PORT |
| CATH · Global X Funds | 0.26% | 14490 NS | 2026年7月31日 | N-PORT |
| BSCQ · Invesco Exchange-Traded Self-Inde... | 0.25% | 7970000 | 2026年10月2日 | 每日 |
| DYNF · BlackRock ETF Trust | 0.25% | 443705 SH | 2026年9月11日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | 0.25% | 21158 SH | 2026年8月19日 | 每日 |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.24% | 1323136 SH | 2026年8月19日 | 每日 |
| SPMO · Invesco Exchange-Traded Fund Trus... | 0.23% | 233192 SH | 2026年10月2日 | 每日 |
| VYM · VANGUARD WHITEHALL FUNDS | 0.23% | 934496 SH | 2026年8月19日 | 每日 |
| ESG · FlexShares Trust | 0.23% | 1320 NS | 2026年7月31日 | N-PORT |
| SIZE · iShares Trust | 0.22% | 3988 SH | 2026年9月11日 | 每日 |
| LRGF · iShares Trust | 0.22% | 33556 SH | 2026年9月11日 | 每日 |
| VTV · VANGUARD INDEX FUNDS | 0.21% | 2225442 SH | 2026年8月19日 | 每日 |
| VFMF · VANGUARD WELLINGTON FUND | 0.21% | 6281 SH | 2026年8月19日 | 每日 |
| EUSA · iShares, Inc. | 0.20% | 16612 SH | 2026年9月11日 | 每日 |
| PFM · Invesco Exchange-Traded Fund Trust | 0.20% | 6670 SH | 2026年10月2日 | 每日 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 813183 SH | 2026年10月2日 | 每日 |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.19% | 53931 SH | 2026年8月19日 | 每日 |
| IVE · iShares Trust | 0.19% | 388621 SH | 2026年9月11日 | 每日 |
| IUSV · iShares Trust | 0.18% | 205310 SH | 2026年9月11日 | 每日 |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.18% | 6098 SH | 2026年10月2日 | 每日 |
| IQSU · New York Life Investments ETF Trust | 0.17% | 2435 NS | 2026年7月31日 | N-PORT |
| CHRI · Global X Funds | 0.16% | 57 NS | 2026年7月31日 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Inde... | 0.16% | 4467000 | 2026年10月2日 | 每日 |
| DSI · iShares Trust | 0.16% | 35796 SH | 2026年9月11日 | 每日 |
| EGLE · Global X Funds | 0.13% | 12 NS | 2026年7月31日 | N-PORT |
| GLBL · Pacer Funds Trust | 0.12% | 6 NS | 2026年7月31日 | N-PORT |
| LQAI · Exchange Listed Funds Trust | 0.12% | 12 NS | 2026年7月31日 | N-PORT |
| DGRO · iShares Trust | 0.12% | 217268 SH | 2026年9月11日 | 每日 |
| VFVA · VANGUARD WELLINGTON FUND | 0.11% | 3797 SH | 2026年8月19日 | 每日 |
| QVML · Invesco Exchange-Traded Fund Trus... | 0.10% | 7530 SH | 2026年10月2日 | 每日 |
| TOPC · iShares Trust | 0.10% | 144 SH | 2026年9月11日 | 每日 |
| ACVF · ETF Opportunities Trust | 0.10% | 675 NS | 2026年7月31日 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.10% | 52911 SH | 2026年8月19日 | 每日 |
| DFSU · Dimensional ETF Trust | 0.10% | 9417 NS | 2026年7月31日 | N-PORT |
| ILCG · iShares Trust | 0.10% | 12549 SH | 2026年9月11日 | 每日 |
| XVV · iShares Trust | 0.09% | 2689 SH | 2026年9月11日 | 每日 |
| USMV · iShares Trust | 0.09% | 91385 SH | 2026年9月11日 | 每日 |
| VOO · VANGUARD INDEX FUNDS | 0.09% | 6082026 SH | 2026年8月19日 | 每日 |
| VV · VANGUARD INDEX FUNDS | 0.09% | 273537 SH | 2026年8月19日 | 每日 |
| XRMI · Global X Funds | 0.09% | 194 NS | 2026年7月31日 | N-PORT |
| XYLG · Global X Funds | 0.09% | 244 NS | 2026年7月31日 | N-PORT |
| XYLD · Global X Funds | 0.09% | 12239 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.08% | 45685 NS | 2026年7月31日 | N-PORT |
| IVV · iShares Trust | 0.08% | 2952119 SH | 2026年9月11日 | 每日 |
| PTLC · Pacer Funds Trust | 0.08% | 11916 NS | 2026年7月31日 | N-PORT |
| XCLR · Global X Funds | 0.08% | 13 NS | 2026年7月31日 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund ... | 0.08% | 32252 NS | 2026年7月31日 | N-PORT |
| VOXP · Advisors Series Trust | 0.08% | 21 NS | 2026年7月31日 | N-PORT |
| ILCB · iShares Trust | 0.08% | 4535 SH | 2026年9月11日 | 每日 |
| VOTE · TCW ETF Trust | 0.08% | 3959 NS | 2026年7月31日 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.08% | 1385 SH | 2026年10月2日 | 每日 |
| BKLC · BNY Mellon ETF Trust | 0.08% | 19424 NS | 2026年7月31日 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trus... | 0.08% | 40564 SH | 2026年10月2日 | 每日 |
| XTR · Global X Funds | 0.08% | 17 NS | 2026年7月31日 | N-PORT |
| IWD · iShares Trust | 0.08% | 282063 SH | 2026年9月11日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.08% | 7436156 SH | 2026年8月19日 | 每日 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.08% | 38624 SH | 2026年8月19日 | 每日 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.08% | 76610 SH | 2026年8月19日 | 每日 |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.08% | 169890 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.08% | 19715 SH | 2026年8月19日 | 每日 |
| TOV · EA Series Trust | 0.08% | 913 NS | 2026年7月31日 | N-PORT |
| IWB · iShares Trust | 0.08% | 162672 SH | 2026年9月11日 | 每日 |
| IYY · iShares Trust | 0.08% | 10064 SH | 2026年9月11日 | 每日 |
| DFUS · Dimensional ETF Trust | 0.08% | 71472 NS | 2026年7月31日 | N-PORT |
| USCL · iShares Trust | 0.08% | 9352 SH | 2026年9月11日 | 每日 |
| SPUU · Direxion Shares ETF Trust | 0.08% | 884 NS | 2026年7月31日 | N-PORT |
| IWF · iShares Trust | 0.08% | 402774 SH | 2026年9月11日 | 每日 |
| QDPL · Pacer Funds Trust | 0.08% | 5627 NS | 2026年7月31日 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.08% | 32168 SH | 2026年10月2日 | 每日 |
| IWV · iShares Trust | 0.08% | 64328 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.08% | 304905 SH | 2026年9月11日 | 每日 |
| ILCV · iShares Trust | 0.07% | 4083 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.07% | 6802 NS | 2026年7月31日 | N-PORT |
| PHDG · Invesco Actively Managed Exchange... | 0.07% | 183 SH | 2026年10月2日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.07% | 9717 NS | 2026年7月31日 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.07% | 1627 NS | 2026年7月31日 | N-PORT |
| TOK · iShares Trust | 0.07% | 656 SH | 2026年9月11日 | 每日 |
| SPXL · Direxion Shares ETF Trust | 0.06% | 18311 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.06% | 129668 NS | 2026年7月31日 | N-PORT |
| URTH · iShares, Inc. | 0.06% | 20873 SH | 2026年9月11日 | 每日 |
| ACWI · iShares Trust | 0.05% | 74784 SH | 2026年9月11日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.05% | 197885 SH | 2026年8月19日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.01% | 343 NS | 2026年7月31日 | N-PORT |
| GTO · Invesco Actively Managed Exchange... | 0.00% | 40400 | 2026年9月30日 | 每日 |
| GTOS · Invesco Actively Managed Exchange... | 0.00% | 600 | 2026年9月30日 | 每日 |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
CAH 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
12个月价格目标
15 位分析师 · 2026-10-02平均目标 $270.33 +18.4%
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。